
- Oncology NEWS International Vol 17 No 2
- Volume 17
- Issue 2
Exelixis/BMS to develop XL139, hedgehog pathway inhibitor
Exelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States.
SOUTH SAN FRANCISCO, CaliforniaExelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States. Hedgehog plays a critical role in regulating cell growth, proliferation, and differentiation, and is deregulated in a variety of cancers, making it a promising target for cancer therapies, Exelixis said.
Articles in this issue
over 17 years ago
NLST article not balanced, critic of screening trial assertsover 17 years ago
M.D. Anderson and AstraZeneca form neuropathic pain allianceover 17 years ago
Good nilotinib responses in imatinib-resistant AP-CMLover 17 years ago
Virus linked to Merkel cell carcinomaover 17 years ago
Benefit of adjuvant RT/CT for pancreatic ca affirmedover 17 years ago
Recurrence Score helps select node+ pts for chemoover 17 years ago
For resectable liver mets: Preop chemotherapy or not?over 17 years ago
Plerixafor boosts stem cell mobilization in myeloma ptsover 17 years ago
MRI shows second-hand smoke damageover 17 years ago
Assay has high sensitivity for hard-to-detect SLN metsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.